Sign in
Not yet recruitingNo phase

Perceived Autonomy in Performing Intravenous Injections for Patients With Severe or Moderate Hemophilia A Receiving Emicizumab

Key facts

Who runs it
University Hospital, Caen
Where
France and Guadeloupe25 sites in 2 countriesChoose a country to see its sites
Trial code
Status
Not yet recruiting
People taking part
450 people, planned
Starts
15 Jan 2027
Expected to end
30 Jun 2028
Type of study
Observational, 2 groups
Record updated
18 November 2026

Who can take part

Sex
Women and men
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 19 criteriaShow less

Who can take part

  • For autonomous adult patients (patient enrolled in the study):
  • Adult patient (>= 18 years old) with severe or moderate hemophilia A
  • Receiving prophylactic treatment with emicizumab for more than 1 year
  • Patient previously autonomous in performing intravenous injections of clotting factor concentrates prior to emicizumab initiation
  • Patient non-opposition obtained; For autonomous pediatric/minor patients (patient enrolled in the study):
  • Minor patient (< 18 years old) with severe or moderate hemophilia A
  • Receiving prophylactic treatment with emicizumab for more than 1 year
  • Patient previously autonomous in performing intravenous injections of clotting factor concentrates prior to emicizumab initiation
  • Patient non-opposition obtained
  • Non-opposition obtained from parents or legal guardians; For non-autonomous pediatric/minor patients (family caregiver enrolled in the study):
  • Parent caregiver of a child with severe or moderate hemophilia A receiving prophylactic treatment with emicizumab for more than 1 year
  • Parent previously autonomous in performing intravenous injections of clotting factor concentrates prior to emicizumab initiation
  • Parent caregiver non-opposition obtained; For healthcare providers:
  • Physician, nurse, or healthcare professional involved in the care of patients with severe or moderate hemophilia A at a participating center
  • Healthcare provider non-opposition obtained

Who cannot take part

  • Patient not autonomous in performing intravenous injections of clotting factor concentrates prior to emicizumab initiation; For autonomous pediatric/minor patients:
  • Patient not autonomous in performing intravenous injections of clotting factor concentrates prior to emicizumab initiation; For non-autonomous pediatric/minor patients:
  • For autonomous adult patients:
  • Parent caregiver who is a healthcare professional

Where is this trial?

It has sites in 2 countries. Choose a country to see its sites.

About the trial

What the trial wants to find out

Hemophilia A is a rare inherited bleeding disorder caused by a deficiency in clotting factor VIII (severe if <1%, moderate if 1% to 5%). Until the introduction of emicizumab (Hemlibra®), treatment relied exclusively on frequent intravenous (IV) infusions of clotting factor concentrates (FVIII or bypassing agents), allowing patients or their family caregivers to maintain technical skills and autonomy through regular practice.

Read full original descriptionShow less

Since 2018 (and 2023 for moderate hemophilia A), subcutaneous prophylactic treatment with emicizumab has drastically reduced bleeding episodes and, consequently, the frequency of IV infusions. However, IV injections remain necessary to treat acute breakthrough bleeds. The investigators hypothesize that previously autonomous patients or family caregivers may experience a gradual loss of skill and self-efficacy in performing IV injections while on emicizumab prophylaxis.

The APHARIPE study is a multicenter, non-interventional, exploratory study based on questionnaires administered to 450 previously autonomous patients with severe or moderate hemophilia A (or their family caregivers) receiving emicizumab, as well as their healthcare providers. Over an 18-month inclusion period, this study aims to assess perceived autonomy in performing IV injections, identify potential perception gaps between patients/caregivers and healthcare providers, evaluate the impact on acute bleed management and home emergency treatment storage, and guide future therapeutic education practices.

The 2 groups in the trial

  • Patients or Family Caregivers

    Patients with severe or moderate hemophilia A (or family caregivers for pediatric) receiving emicizumab prophylaxis who were previously autonomous in performing intravenous clotting factor injections. Participants will complete a structured questionnaire assessing their perceived autonomy and self-efficacy

  • Healthcare Providers

    Healthcare professionals (physicians, nurses) caring for patients with hemophilia A at participating centers. Participants will complete a specific questionnaire evaluating their perception of patients' potential loss of autonomy for intravenous injections and its impact on clinical management

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Perceived Autonomy of Patients (or Family Caregivers) With Severe or Moderate Hemophilia A for Performing Intravenous Injections Under Emicizumab Prophylaxis
Record updated
18 November 2026